Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute discusses the future impact of new therapies for renal cell carcinoma treatment at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Which areas of RCC will impact the treatment landscape in the next 1-3 years?
